Text written in Basque and translated automatically by Elia without any subsequent editing. SEE ORIGINAL

It is announced that an RNA vaccine against melanoma has passed phase III

It is a custom vaccine in which the messenger RNA contains instructions for producing certain signals from cancer cells

The pharmaceutical companies Merck and Moderna announce that the melanoma vaccine has passed phase III of clinical trials. The forecast has raised expectations and both companies have experienced a significant growth in the stock market. But for now, the results have not been published in a scientific journal and, even if everything goes well, it still has to make its way to be accepted and accessible to patients.

The vaccine is based on messenger RNA technology. This technology became popular during the COVID-19 pandemic and consists of injecting messenger RNA that encodes instructions for the production of antigenic proteins. In the case of melanoma, it is a custom vaccine that contains instructions for the production of certain signals from cancer cells by messenger RNA. Thus, through these signals, the immune system generates a response against cancer cells.

“The clinical trial involved 1,137 patients with high-risk skin melanoma types III and IV.”

In addition to messenger RNA, the vaccine also carries an immunotherapy treatment, pembrolizumab. The clinical trial involved 1,137 patients with high-risk skin melanoma types III and IV. Previously, they had surgery to remove the tumor and researchers have created a vaccine against each patient’s tumor cells.

The results have been promising, but they have not yet been presented through a scientific article. Therefore, the scientific community has not had the opportunity to see and analyze the details. All on the right track, the next step would be to pass the drug agency exam. Therefore, at the moment it is in the experimental phase and if it is admitted it will be for a certain type of patients.